SK282944B6 - Tavené tropánové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

Tavené tropánové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number: SK282944B6
Authority: SK; Slovakia
Prior art keywords: dichlorophenyl; azatricyclo; alkyl; tricyclo; decan
Prior art date: 1995-11-02

Application number

SK422-98A

Other languages

English (en)

Slovak (sk)

Other versions

SK42298A3 (en

Inventor

Jorgen Scheel-Kr�Ger

Gunnar M. Olsen

Elsebet Ostergaard Nielsen

Bjarne Hugo Dahl

Leif Helh Jensen

Original Assignee

Neurosearch A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-02

Filing date

1996-11-04

Publication date

2003-01-09

1996-11-04 Application filed by Neurosearch A/S filed Critical Neurosearch A/S

1998-10-07 Publication of SK42298A3 publication Critical patent/SK42298A3/sk

2003-01-09 Publication of SK282944B6 publication Critical patent/SK282944B6/sk

Links

150000003813 tropane derivatives Chemical class 0.000 title claims description 7
239000003901 neurotransmitter uptake inhibitor Substances 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 75
239000000203 mixture Substances 0.000 claims abstract description 31
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
239000001257 hydrogen Substances 0.000 claims abstract description 18
125000000217 alkyl group Chemical group 0.000 claims abstract description 17
150000003839 salts Chemical class 0.000 claims abstract description 16
239000002858 neurotransmitter agent Substances 0.000 claims abstract description 13
150000002431 hydrogen Chemical class 0.000 claims abstract description 9
229910052736 halogen Inorganic materials 0.000 claims abstract description 8
150000002367 halogens Chemical class 0.000 claims abstract description 8
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 7
229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
150000001204 N-oxides Chemical class 0.000 claims abstract description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 3
125000001424 substituent group Chemical group 0.000 claims abstract description 3
229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 2
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 106
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 36
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 33
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
JDPQWHLMBJZURR-UHFFFAOYSA-N decan-5-one Chemical compound CCCCCC(=O)CCCC JDPQWHLMBJZURR-UHFFFAOYSA-N 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 19
208000035475 disorder Diseases 0.000 claims description 16
SZMNDOUFZGODBR-UHFFFAOYSA-N decan-5-ol Chemical compound CCCCCC(O)CCCC SZMNDOUFZGODBR-UHFFFAOYSA-N 0.000 claims description 15
SKYXHNSTAUDQDO-UHFFFAOYSA-N CCCCCC(=NOC)CCCC Chemical compound CCCCCC(=NOC)CCCC SKYXHNSTAUDQDO-UHFFFAOYSA-N 0.000 claims description 14
230000005764 inhibitory process Effects 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 13
-1 dec-5-yl Chemical group 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
KMPQYAYAQWNLME-UHFFFAOYSA-N undecanal Chemical compound CCCCCCCCCCC=O KMPQYAYAQWNLME-UHFFFAOYSA-N 0.000 claims description 12
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 11
230000002401 inhibitory effect Effects 0.000 claims description 11
125000001624 naphthyl group Chemical group 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
RHGBQXWLNNXERI-UHFFFAOYSA-N n-decan-5-ylidenehydroxylamine Chemical compound CCCCCC(=NO)CCCC RHGBQXWLNNXERI-UHFFFAOYSA-N 0.000 claims description 9
208000008589 Obesity Diseases 0.000 claims description 8
208000013403 hyperactivity Diseases 0.000 claims description 8
235000020824 obesity Nutrition 0.000 claims description 8
230000000697 serotonin reuptake Effects 0.000 claims description 8
208000019901 Anxiety disease Diseases 0.000 claims description 7
PPTDEGLNCJWPPG-UHFFFAOYSA-N C(C1=CC=CC=C1)ON=C(CCCC)CCCCC Chemical compound C(C1=CC=CC=C1)ON=C(CCCC)CCCCC PPTDEGLNCJWPPG-UHFFFAOYSA-N 0.000 claims description 7
208000030814 Eating disease Diseases 0.000 claims description 7
208000019454 Feeding and Eating disease Diseases 0.000 claims description 7
208000026139 Memory disease Diseases 0.000 claims description 7
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 7
235000014632 disordered eating Nutrition 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
208000020401 Depressive disease Diseases 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
230000004044 response Effects 0.000 claims description 5
206010029333 Neurosis Diseases 0.000 claims description 4
210000003169 central nervous system Anatomy 0.000 claims description 4
AYZMTNBVPCPWOC-UHFFFAOYSA-N decan-5-yl acetate Chemical compound CCCCCC(OC(C)=O)CCCC AYZMTNBVPCPWOC-UHFFFAOYSA-N 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
208000015238 neurotic disease Diseases 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
208000026097 Factitious disease Diseases 0.000 claims description 3
QSTKDAVWTSTQTD-UHFFFAOYSA-N C(C)ON=C(CCCC)CCCCC Chemical compound C(C)ON=C(CCCC)CCCCC QSTKDAVWTSTQTD-UHFFFAOYSA-N 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
230000001561 neurotransmitter reuptake Effects 0.000 claims description 2
XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical group C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 2
GFSGLVOIZVSBNJ-UHFFFAOYSA-N C(C)(C)(C)ON=C(CCCC)CCCCC Chemical compound C(C)(C)(C)ON=C(CCCC)CCCCC GFSGLVOIZVSBNJ-UHFFFAOYSA-N 0.000 claims 2
AXHNHGWBVFCLFB-CIGZNWKYSA-N (1S,2S,4S,7R)-2-(3,4-dichlorophenyl)-8-azatricyclo[5.4.0.04,8]undecan-11-one Chemical compound C1([C@@H]2[C@]3([H])C(=O)CCN4[C@]3([H])CC[C@]4(C2)[H])=CC=C(Cl)C(Cl)=C1 AXHNHGWBVFCLFB-CIGZNWKYSA-N 0.000 claims 1
MTCWULTWUZAUJI-NHIYQJMISA-N (1S,2S,4S,7R)-2-(4-chlorophenyl)-8-azatricyclo[5.4.0.04,8]undecan-11-one Chemical compound C1([C@@H]2[C@]3([H])C(=O)CCN4[C@]3([H])CC[C@]4(C2)[H])=CC=C(Cl)C=C1 MTCWULTWUZAUJI-NHIYQJMISA-N 0.000 claims 1
208000012902 Nervous system disease Diseases 0.000 claims 1
125000000068 chlorophenyl group Chemical group 0.000 claims 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 25
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 22
229960003638 dopamine Drugs 0.000 abstract description 14
125000003118 aryl group Chemical group 0.000 abstract description 6
239000003112 inhibitor Substances 0.000 abstract description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 2
125000003342 alkenyl group Chemical group 0.000 abstract 6
125000000304 alkynyl group Chemical group 0.000 abstract 6
125000003710 aryl alkyl group Chemical group 0.000 abstract 4
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 65
239000003921 oil Substances 0.000 description 61
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 38
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
239000011541 reaction mixture Substances 0.000 description 35
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
239000000243 solution Substances 0.000 description 34
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 27
239000004480 active ingredient Substances 0.000 description 22
239000002552 dosage form Substances 0.000 description 22
229910052943 magnesium sulfate Inorganic materials 0.000 description 19
235000019341 magnesium sulphate Nutrition 0.000 description 19
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
239000002775 capsule Substances 0.000 description 14
229960002748 norepinephrine Drugs 0.000 description 13
239000000047 product Substances 0.000 description 13
239000007787 solid Substances 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
235000011114 ammonium hydroxide Nutrition 0.000 description 12
239000000843 powder Substances 0.000 description 12
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 11
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
239000013078 crystal Substances 0.000 description 11
239000001530 fumaric acid Substances 0.000 description 11
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 11
239000012074 organic phase Substances 0.000 description 11
239000003826 tablet Substances 0.000 description 11
235000019441 ethanol Nutrition 0.000 description 10
239000006260 foam Substances 0.000 description 10
239000000126 substance Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
239000000460 chlorine Substances 0.000 description 9
239000012458 free base Substances 0.000 description 9
239000007788 liquid Substances 0.000 description 9
229940076279 serotonin Drugs 0.000 description 9
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
UVWQOCCVTJMDGE-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.C(C)(=O)OC(CCCC)CCCCC Chemical compound C(\C=C\C(=O)O)(=O)O.C(C)(=O)OC(CCCC)CCCCC UVWQOCCVTJMDGE-WLHGVMLRSA-N 0.000 description 8
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 8
238000001914 filtration Methods 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
230000005978 brain dysfunction Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000002825 dopamine reuptake Effects 0.000 description 7
238000010992 reflux Methods 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
DUMMLBFJPQGNSA-WLHGVMLRSA-N (e)-but-2-enedioic acid;decane Chemical compound OC(=O)\C=C\C(O)=O.CCCCCCCCCC DUMMLBFJPQGNSA-WLHGVMLRSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
230000001430 anti-depressive effect Effects 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
239000002585 base Substances 0.000 description 6
238000011534 incubation Methods 0.000 description 6
125000000896 monocarboxylic acid group Chemical group 0.000 description 6
229960001779 pargyline Drugs 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
239000003772 serotonin uptake inhibitor Substances 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
239000011734 sodium Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
229910000104 sodium hydride Inorganic materials 0.000 description 6
239000002904 solvent Substances 0.000 description 6
230000009870 specific binding Effects 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 6
VEGFYRHBKRVBTI-UHFFFAOYSA-N Cl.CCCCC(CCCCC)=NO Chemical compound Cl.CCCCC(CCCCC)=NO VEGFYRHBKRVBTI-UHFFFAOYSA-N 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
OKBLKFGUDUIZMU-TVFIUFHYSA-N methyl (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-(2-ethoxy-2-oxoethyl)-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@@H]2[C@H]([C@]3(CC[C@@](C2)(N3CC(=O)OCC)[H])[H])C(=O)OC)=CC=C(Cl)C(Cl)=C1 OKBLKFGUDUIZMU-TVFIUFHYSA-N 0.000 description 5
STJIRUUYHOSQEE-UHFFFAOYSA-N n-methoxyundecan-1-imine Chemical compound CCCCCCCCCCC=NOC STJIRUUYHOSQEE-UHFFFAOYSA-N 0.000 description 5
239000007921 spray Substances 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
210000003568 synaptosome Anatomy 0.000 description 5
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
235000010323 ascorbic acid Nutrition 0.000 description 4
239000011668 ascorbic acid Substances 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229960003920 cocaine Drugs 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
JEEZTCZXQWPJAS-QHDJUILOSA-N ethyl (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-(3-ethoxy-3-oxopropyl)-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@@H]2[C@H]([C@]3(CC[C@@](C2)(N3CCC(=O)OCC)[H])[H])C(=O)OCC)=CC=C(Cl)C(Cl)=C1 JEEZTCZXQWPJAS-QHDJUILOSA-N 0.000 description 4
AWYMPFPLGDNYAJ-RBDSIQFVSA-N ethyl (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@@H]2[C@H]([C@@]3([H])CC[C@](N3)(C2)[H])C(=O)OCC)=CC=C(Cl)C(Cl)=C1 AWYMPFPLGDNYAJ-RBDSIQFVSA-N 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
DXYSRTGYTVGMNO-BVIKNXMNSA-N methyl (1s,3s,4r,5r)-3-(4-chlorophenyl)-8-(2-ethoxy-2-oxoethyl)-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@@H]2[C@H]([C@]3(CC[C@@](C2)(N3CC(=O)OCC)[H])[H])C(=O)OC)=CC=C(Cl)C=C1 DXYSRTGYTVGMNO-BVIKNXMNSA-N 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000012071 phase Substances 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
XASNGMATMHZRQB-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.C(C)(C)(C)ON=C(CCCC)CCCCC Chemical compound C(\C=C\C(=O)O)(=O)O.C(C)(C)(C)ON=C(CCCC)CCCCC XASNGMATMHZRQB-WLHGVMLRSA-N 0.000 description 3
QVWMPLKFANBTEQ-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.C(C)ON=C(CCCC)CCCCC Chemical compound C(\C=C\C(=O)O)(=O)O.C(C)ON=C(CCCC)CCCCC QVWMPLKFANBTEQ-WLHGVMLRSA-N 0.000 description 3
MCLCAICSPBOZRR-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.CCCCC(CCCCC)=O Chemical compound C(\C=C\C(=O)O)(=O)O.CCCCC(CCCCC)=O MCLCAICSPBOZRR-WLHGVMLRSA-N 0.000 description 3
GGYWAAYMGLKTJZ-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.CCCCC(CCCCC)O Chemical compound C(\C=C\C(=O)O)(=O)O.CCCCC(CCCCC)O GGYWAAYMGLKTJZ-WLHGVMLRSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
102000010909 Monoamine Oxidase Human genes 0.000 description 3
108010062431 Monoamine oxidase Proteins 0.000 description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700157 Rattus norvegicus Species 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000027455 binding Effects 0.000 description 3
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 3
239000003086 colorant Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000013355 food flavoring agent Nutrition 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000003365 glass fiber Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
230000000966 norepinephrine reuptake Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
238000002798 spectrophotometry method Methods 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
239000008096 xylene Substances 0.000 description 3
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
APEZWEXOPQBEOQ-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.CCCCC(CCCCC)N Chemical compound C(\C=C\C(=O)O)(=O)O.CCCCC(CCCCC)N APEZWEXOPQBEOQ-WLHGVMLRSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 2
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
UTKBLLDLHPDWDU-TYYBGVCCSA-N acetic acid;(e)-but-2-enedioic acid Chemical compound CC(O)=O.OC(=O)\C=C\C(O)=O UTKBLLDLHPDWDU-TYYBGVCCSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
201000007930 alcohol dependence Diseases 0.000 description 2
230000036626 alertness Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229960001653 citalopram Drugs 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
229960003914 desipramine Drugs 0.000 description 2
XLFWHXZCZSUEDV-UAXWRAGISA-N ethyl (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2C(=O)OCC)=CC=C(Cl)C(Cl)=C1 XLFWHXZCZSUEDV-UAXWRAGISA-N 0.000 description 2
FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 2
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
239000006210 lotion Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
AMIHUYQKNJHXPT-RBDSIQFVSA-N methyl (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@@H]2[C@H]([C@]3(CC[C@@](C2)(N3C)[H])[H])C(=O)OC)=CC=C(Cl)C(Cl)=C1 AMIHUYQKNJHXPT-RBDSIQFVSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
OAEYFMLPKMPMML-BJJYAFAJSA-N (1s,3s,4s,8r)-3-(3,4-dichlorophenyl)-5-methoxy-7-azatricyclo[5.3.0.04,8 ]decane Chemical compound C1([C@@H]2[C@]3([H])C(OC)CN4[C@]3([H])CC[C@]4(C2)[H])=CC=C(Cl)C(Cl)=C1 OAEYFMLPKMPMML-BJJYAFAJSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
CHDSCOABJUJHGB-UHFFFAOYSA-N CON=C(CCCC)CCCCCCC Chemical compound CON=C(CCCC)CCCCCCC CHDSCOABJUJHGB-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010028403 Mutism Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
206010036631 Presenile dementia Diseases 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
AVVKACMTIMCTRF-UHFFFAOYSA-N S(=O)(=O)(O)O.CCCCC(CCCCC)C Chemical compound S(=O)(=O)(O)O.CCCCC(CCCCC)C AVVKACMTIMCTRF-UHFFFAOYSA-N 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010043903 Tobacco abuse Diseases 0.000 description 1
NLHLPCAILIBESH-MCPLSKDVSA-N [(1S,3S,4S,8R)-3-(3,4-dichlorophenyl)-7-azatricyclo[5.3.0.04,8]decan-5-yl] acetate Chemical compound C1([C@@H]2[C@]3([H])C(OC(C)=O)CN4[C@]3([H])CC[C@]4(C2)[H])=CC=C(Cl)C(Cl)=C1 NLHLPCAILIBESH-MCPLSKDVSA-N 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
230000037007 arousal Effects 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
210000001653 corpus striatum Anatomy 0.000 description 1
210000005080 cortical synaptosome Anatomy 0.000 description 1
KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
229940008406 diethyl sulfate Drugs 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
230000028436 dopamine uptake Effects 0.000 description 1
239000000221 dopamine uptake inhibitor Substances 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
PRQICMQRAXJOCP-ZHZAVPAVSA-N methyl (1r,3s,5r)-3-(4-chlorophenyl)-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@@H]2C([C@@]3([H])CC[C@@](N3)(C2)[H])C(=O)OC)=CC=C(Cl)C=C1 PRQICMQRAXJOCP-ZHZAVPAVSA-N 0.000 description 1
FZXFNVPTYNGFCH-DODZYUBVSA-N methyl (1s,3s,4r,5r)-3-(4-chlorophenyl)-8-(3-ethoxy-3-oxopropyl)-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@@H]2[C@H]([C@]3(CC[C@@](C2)(N3CCC(=O)OCC)[H])[H])C(=O)OC)=CC=C(Cl)C=C1 FZXFNVPTYNGFCH-DODZYUBVSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
230000000407 monoamine reuptake Effects 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
230000007372 neural signaling Effects 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
206010036596 premature ejaculation Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
WENNKWXPAWNIOO-UHFFFAOYSA-N undecan-5-one Chemical compound CCCCCCC(=O)CCCC WENNKWXPAWNIOO-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000011345 viscous material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Exhaust Gas After Treatment (AREA)
Ultra Sonic Daignosis Equipment (AREA)

SK422-98A 1995-11-02 1996-11-04 Tavené tropánové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie SK282944B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DK122395		1995-11-02
DK14696		1996-02-13
PCT/EP1996/004793 WO1997016451A1 (en)	1995-11-02	1996-11-04	Fused tropane-derivatives as neurotransmitter reuptake inhibitors

Publications (2)

Publication Number	Publication Date
SK42298A3 SK42298A3 (en)	1998-10-07
SK282944B6 true SK282944B6 (sk)	2003-01-09

Family

ID=26063395

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK422-98A SK282944B6 (sk)	1995-11-02	1996-11-04	Tavené tropánové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (24)

Country	Link
US (1)	US5998405A (et)
EP (1)	EP0858461B1 (et)
JP (1)	JP3157839B2 (et)
KR (1)	KR100277482B1 (et)
CN (1)	CN1060775C (et)
AT (1)	ATE224392T1 (et)
AU (1)	AU702720B2 (et)
BR (1)	BR9611300A (et)
CA (1)	CA2236707C (et)
CZ (1)	CZ285571B6 (et)
DE (1)	DE69623799T2 (et)
DK (1)	DK0858461T3 (et)
EE (1)	EE03566B1 (et)
HU (1)	HUP9802534A3 (et)
IL (1)	IL123898A (et)
IS (1)	IS4708A (et)
NO (1)	NO309569B1 (et)
NZ (1)	NZ321970A (et)
PL (1)	PL184843B1 (et)
RU (1)	RU2162469C2 (et)
SK (1)	SK282944B6 (et)
TR (1)	TR199800780T2 (et)
UA (1)	UA47442C2 (et)
WO (1)	WO1997016451A1 (et)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6706880B2 (en)	1990-08-09	2004-03-16	Research Triangle Institute	Cocaine receptor binding ligands
US6329520B1 (en) *	1990-08-09	2001-12-11	Research Triangle Institute	Cocaine receptor binding ligands
US6150376A (en) *	1998-08-05	2000-11-21	Georgetown University	Bi- and tri-cyclic aza compounds and their uses
ID27544A (id) *	1998-08-18	2001-04-12	Ucb Sa	Agonis dan antagonis muskarinat
WO2001023385A2 (en) *	1999-09-27	2001-04-05	Georgetown University	Novel tropane analogs
US6479509B1 (en)	2000-05-22	2002-11-12	Research Triangle Institute	Method of promoting smoking cessation
WO2002002559A1 (en) *	2000-07-04	2002-01-10	Neurosearch A/S	Steric isomers of fused tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
DE60231386D1 (de)	2001-04-09	2009-04-16	Neurosearch As	Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
WO2002094827A1 (en) *	2001-05-23	2002-11-28	Neurosearch A/S	Fused tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR035898A1 (es)	2001-05-25	2004-07-21	Wyeth Corp	Aril-8-azabiciclo[3.2.1]octanos, un proceso para su preparacion, una formulacion y el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de la depresion
US7381733B2 (en)	2001-11-30	2008-06-03	Neurosearch A/S	Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
JP2006517567A (ja)	2003-02-12	2006-07-27	ニューロサーチ、アクティーゼルスカブ	新規８−アザ−ビシクロ［３．２．１］オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法
CA2515584A1 (en)	2003-02-12	2004-08-26	Neurosearch A/S	8-aza-bicyclo (3.2.1) octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CN100356940C (zh) *	2004-12-01	2007-12-26	蒋毅	制备大叶蒟提取物的方法、提取物及其应用
US20090137625A1 (en)	2005-04-08	2009-05-28	Dan Peters	Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors
US7943630B2 (en)	2005-06-28	2011-05-17	Neurosearch A/S	3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
ATE481386T1 (de)	2005-06-28	2010-10-15	Neurosearch As	Neue 3-aza-spiroä5.5üundec-8-en derivate und deren verwendung als inhibitoren der wiederaufnahme von monoaminneurotransmittern
EP1916985A4 (en) *	2005-08-19	2010-06-09	Elan Pharm Inc	BRIDGED N-CYCLIC SULPHONAMIDE INHIBITORS OF THE GAMMED CRYSTETRY
TW200800980A (en)	2006-02-17	2008-01-01	Neurosearch As	Novel compounds
JP2012526744A (ja)	2009-05-15	2012-11-01	ノイロサーチアクティーゼルスカブ	クロメン−２−オン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用
KR20120044978A (ko) *	2009-06-19	2012-05-08	아보트 러보러터리즈	디아자호모아다만탄 유도체 및 이들의 사용 방법
US20120220604A1 (en)	2009-09-21	2012-08-30	Neurosearch A/S	Piperazinyl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011092061A1 (en)	2010-01-29	2011-08-04	Neurosearch A/S	Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011117289A1 (en)	2010-03-25	2011-09-29	Neurosearch A/S	Chromen-2-one derivatives and their use as monoamine neuro-transmitter re-uptake inhibitors
WO2012000881A1 (en)	2010-07-02	2012-01-05	Neurosearch A/S	Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP6052524B1 (ja) *	2015-07-30	2016-12-27	秋夫湯田	持ち運び設置が容易な手提げハンドルの付いた薪ストーブ。
PL4551221T3 (pl)	2022-07-08	2026-04-20	Initiator Pharma A/S	Związek do leczenia dysfunkcji seksualnych u samic/kobiet
CN120129523A (zh)	2022-10-28	2025-06-10	创始人制药股份有限公司	用于治疗疼痛的化合物
CN120813353A (zh)	2023-01-03	2025-10-17	创始人制药股份有限公司	用于治疗勃起功能障碍的化合物
WO2025051846A1 (en)	2023-09-05	2025-03-13	Initiator Pharma A/S	Compound for treatment of female sexual dysfunction
KR20250050681A (ko)	2023-10-08	2025-04-15	임종완	이중관형멀티커넥터

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU672644B2 (en) *	1992-12-23	1996-10-10	Neurosearch A/S	Aryl substituted heterocyclic compounds
EE03877B1 (et) *	1994-04-19	2002-10-15	Neurosearch A/S	Tropaan-2-aldoksiimi derivaadid neurotransmitteritagasihaarde inhibiitoritena

1996
- 1996-11-04 AU AU75631/96A patent/AU702720B2/en not_active Ceased
- 1996-11-04 EE EE9800100A patent/EE03566B1/et not_active IP Right Cessation
- 1996-11-04 IL IL12389896A patent/IL123898A/en not_active IP Right Cessation
- 1996-11-04 SK SK422-98A patent/SK282944B6/sk unknown
- 1996-11-04 RU RU98110007/04A patent/RU2162469C2/ru not_active IP Right Cessation
- 1996-11-04 CZ CZ981138A patent/CZ285571B6/cs not_active IP Right Cessation
- 1996-11-04 CA CA002236707A patent/CA2236707C/en not_active Expired - Fee Related
- 1996-11-04 HU HU9802534A patent/HUP9802534A3/hu unknown
- 1996-11-04 DK DK96938064T patent/DK0858461T3/da active
- 1996-11-04 TR TR1998/00780T patent/TR199800780T2/xx unknown
- 1996-11-04 BR BR9611300A patent/BR9611300A/pt not_active Application Discontinuation
- 1996-11-04 PL PL96326448A patent/PL184843B1/pl unknown
- 1996-11-04 NZ NZ321970A patent/NZ321970A/en unknown
- 1996-11-04 AT AT96938064T patent/ATE224392T1/de not_active IP Right Cessation
- 1996-11-04 US US09/051,107 patent/US5998405A/en not_active Expired - Lifetime
- 1996-11-04 CN CN96198012A patent/CN1060775C/zh not_active Expired - Fee Related
- 1996-11-04 WO PCT/EP1996/004793 patent/WO1997016451A1/en not_active Ceased
- 1996-11-04 JP JP51708397A patent/JP3157839B2/ja not_active Expired - Fee Related
- 1996-11-04 KR KR1019980702592A patent/KR100277482B1/ko not_active Expired - Fee Related
- 1996-11-04 UA UA98041933A patent/UA47442C2/uk unknown
- 1996-11-04 EP EP96938064A patent/EP0858461B1/en not_active Expired - Lifetime
- 1996-11-04 DE DE69623799T patent/DE69623799T2/de not_active Expired - Lifetime
1998
- 1998-03-31 IS IS4708A patent/IS4708A/is unknown
- 1998-04-07 NO NO981609A patent/NO309569B1/no unknown

Also Published As

Publication number	Publication date
HUP9802534A3 (en)	1999-06-28
DE69623799D1 (de)	2002-10-24
IS4708A (is)	1998-03-31
IL123898A (en)	2001-08-08
PL184843B1 (pl)	2002-12-31
TR199800780T2 (xx)	1998-07-21
DK0858461T3 (da)	2003-01-27
AU702720B2 (en)	1999-03-04
NZ321970A (en)	2000-02-28
WO1997016451A1 (en)	1997-05-09
HK1016984A1 (en)	1999-11-12
EE03566B1 (et)	2001-12-17
CN1060775C (zh)	2001-01-17
BR9611300A (pt)	1999-06-15
US5998405A (en)	1999-12-07
IL123898A0 (en)	1998-10-30
AU7563196A (en)	1997-05-22
EP0858461A1 (en)	1998-08-19
CZ113898A3 (cs)	1998-07-15
NO309569B1 (no)	2001-02-19
CA2236707C (en)	2002-08-06
JP3157839B2 (ja)	2001-04-16
KR19990064111A (ko)	1999-07-26
NO981609D0 (no)	1998-04-07
MX9803554A (es)	1998-09-30
EE9800100A (et)	1998-10-15
CN1201461A (zh)	1998-12-09
KR100277482B1 (ko)	2001-01-15
PL326448A1 (en)	1998-09-28
NO981609L (no)	1998-06-26
UA47442C2 (uk)	2002-07-15
SK42298A3 (en)	1998-10-07
CA2236707A1 (en)	1997-05-09
CZ285571B6 (cs)	1999-09-15
EP0858461B1 (en)	2002-09-18
RU2162469C2 (ru)	2001-01-27
DE69623799T2 (de)	2003-01-30
ATE224392T1 (de)	2002-10-15
HUP9802534A2 (hu)	1999-04-28
JPH11514638A (ja)	1999-12-14

Publication	Publication Date	Title
RU2162469C2 (ru)	2001-01-27	Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов
US6395748B2 (en)	2002-05-28	Tropane-derivatives, their preparation and use
US6100275A (en)	2000-08-08	8-azabicyclo[3.2.1.]oct-2-ene derivatives, their preparation and use
EP0981515B1 (en)	2003-08-27	Piperidine derivatives as neurotransmitter re-uptake inhibitors
JP4588444B2 (ja)	2010-12-01	ジアザビシクロノナン及び−デカン誘導体並びにこれをオピオイドレセプターリガンドとして使用する方法
JP2006517567A (ja)	2006-07-27	新規８−アザ−ビシクロ［３．２．１］オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法
MXPA98003554A (en)	1998-11-16	Frozen tropan derivatives, its preparation and
EP2272847A1 (en)	2011-01-12	Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors
JP2010501624A (ja)	2010-01-21	新規なピペリジン誘導体及びモノアミン神経伝達物質再取込み阻害剤としてのその使用
JP2011513461A (ja)	2011-04-28	ニコチン性アセチルコリン受容体モジュレーターとして有用な新規な１，４−ジアザ−ビシクロ［３．２．１］オクタン誘導体